Literature DB >> 16783841

'Normal counterparts' of nodal peripheral T-cell lymphoma.

Thomas Rüdiger1, Eva Geissinger, Hans Konrad Müller-Hermelink.   

Abstract

Peripheral T-cell lymphomas (PTCL) have been difficult to classify. A homogeneous principle of classification is still lacking, partly because lymph node compartments containing functionally distinct T-cell subsets have not been identified. A correlation to differentiated T-cell subsets, as CD4(+) or CD8(+) cells as well as cytotoxic populations has not revealed clinically meaningful entities. Upon antigen encounter, mature T-cells pass through distinct stages characterized by their surface molecule expression. Naïve T-cells are CD45RA(+)/CD45R0(-)/CD27(+)/CCR7(+), however, after antigen contact CD45RA expression is replaced by CD45R0. They differentiate to central memory cells, which retain CD27 and CCR7, or to effector-memory cells, which loose expression of both molecules depending on the strength of the antigen interaction. Immunohistological analysis of PTCL showed an effector or effector-memory cell phenotype (CD45RA(-)/CD45R0(+)/CD27(-)) for both angioimmunoblastic T-cell lymphoma (AILT) and anaplastic large cell lymphoma (ALCL), but different cytotoxic and activation markers expressed by these tumours. A subset of CD4(+) PTCL-not otherwise specified (PTCL-NOS) may correspond to a central memory cell phenotype (CD45RA(-)/CD45R0(+)/CD27(+)). Thus, a correlation of PTCL to stages of differentiation, rather than to the direction of differentiation, may reveal homogeneous categories. A comparison between the lymphomas and their normal counterparts may contribute to the understanding of the underlying transformation mechanisms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16783841     DOI: 10.1002/hon.786

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  10 in total

1.  EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

Authors:  J J M van Dongen; L Lhermitte; S Böttcher; J Almeida; V H J van der Velden; J Flores-Montero; A Rawstron; V Asnafi; Q Lécrevisse; P Lucio; E Mejstrikova; T Szczepański; T Kalina; R de Tute; M Brüggemann; L Sedek; M Cullen; A W Langerak; A Mendonça; E Macintyre; M Martin-Ayuso; O Hrusak; M B Vidriales; A Orfao
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

2.  TCR-dependent transformation of mature memory phenotype T cells in mice.

Authors:  Xi Wang; Miriam B F Werneck; Boris G Wilson; Hye-Jung Kim; Michael J Kluk; Christopher S Thom; Jonathan W Wischhusen; Julia A Evans; Jonathan L Jesneck; Phuong Nguyen; Courtney G Sansam; Harvey Cantor; Charles W M Roberts
Journal:  J Clin Invest       Date:  2011-09-19       Impact factor: 14.808

3.  Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma.

Authors:  Javeed Iqbal; Dennis D Weisenburger; Timothy C Greiner; Julie M Vose; Timothy McKeithan; Can Kucuk; Huimin Geng; Karen Deffenbacher; Lynette Smith; Karen Dybkaer; Shigeo Nakamura; Masao Seto; Jan Delabie; Francoise Berger; Florence Loong; Wing Y Au; Young-Hyeh Ko; Ivy Sng; James Olen Armitage; Wing C Chan
Journal:  Blood       Date:  2009-11-18       Impact factor: 22.113

4.  NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells.

Authors:  Chiara Ambrogio; Cinzia Martinengo; Claudia Voena; Fabrizio Tondat; Ludovica Riera; Paola Francia di Celle; Giorgio Inghirami; Roberto Chiarle
Journal:  Cancer Res       Date:  2009-11-03       Impact factor: 12.701

5.  The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation.

Authors:  Chiara Ambrogio; Claudia Voena; Andrea D Manazza; Cinzia Martinengo; Carlotta Costa; Tomas Kirchhausen; Emilio Hirsch; Giorgio Inghirami; Roberto Chiarle
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

6.  Inhibition of Rac controls NPM-ALK-dependent lymphoma development and dissemination.

Authors:  A Colomba; S Giuriato; E Dejean; K Thornber; G Delsol; H Tronchère; F Meggetto; B Payrastre; F Gaits-Iacovoni
Journal:  Blood Cancer J       Date:  2011-06-03       Impact factor: 11.037

7.  Pediatric T- and NK-cell lymphomas: new biologic insights and treatment strategies.

Authors:  N K El-Mallawany; J K Frazer; P Van Vlierberghe; A A Ferrando; S Perkins; M Lim; Y Chu; M S Cairo
Journal:  Blood Cancer J       Date:  2012-04-13       Impact factor: 11.037

Review 8.  Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies.

Authors:  C Agostinelli; P P Piccaluga; P Went; M Rossi; A Gazzola; S Righi; T Sista; C Campidelli; P L Zinzani; B Falini; S A Pileri
Journal:  J Clin Pathol       Date:  2008-08-28       Impact factor: 3.411

Review 9.  Burrowing through the Heterogeneity: Review of Mouse Models of PTCL-NOS.

Authors:  Christine E Cutucache; Tyler A Herek
Journal:  Front Oncol       Date:  2016-09-26       Impact factor: 6.244

10.  A preclinical model of peripheral T-cell lymphoma GATA3 reveals DNA damage response pathway vulnerability.

Authors:  Elizabeth A Kuczynski; Giulia Morlino; Alison Peter; Anna M L Coenen-Stass; Jennifer I Moss; Neha Wali; Oona Delpuech; Avinash Reddy; Anisha Solanki; Charles Sinclair; Dinis P Calado; Larissa S Carnevalli
Journal:  EMBO Mol Med       Date:  2022-05-05       Impact factor: 14.260

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.